Emerging Therapies in Castrate-Resistant Prostate Cancer

Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivatio...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2010-05, Vol.11 (3), p.152-158
Main Authors: Zarour, Luai, Alumkal, Joshi
Format: Article
Language:English
Subjects:
Androgen Antagonists - therapeutic use
Androgens - metabolism
Cancer Vaccines - therapeutic use
Histone Deacetylase Inhibitors - therapeutic use
Humans
Lyases - antagonists & inhibitors
Male
Medicine
Medicine & Public Health
Nephrology
Orchiectomy - methods
Prevalence
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - surgery
Survival Rate - trends
Treatment Outcome
United States - epidemiology
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.
ISSN:1527-2737
1534-6285
DOI:10.1007/s11934-010-0104-x